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Introduction: Patients who undergo a percutaneous aortic valve implantation (TAVI) are generally discharged on dual antiplatelet therapy (DAT). 
On the other hand, many of these patients also have an indication for anticoagulant (AC) therapy: it is not clear which is the best treatment in such 
patients.
Methods: We retrospectively analyzed data of 360 patients who underwent TAVI at our centre; patients without any indication for AC served as the 
control group.
Results: 60 patients (16.7%) had one or more indications to AC therapy, mainly because of atrial fibrillation (AF) with a high thrombotic risk 
(n=56). According to clinical evaluation, these 60 patients were discharged in different therapeutic regimens (see table). In one case AC + DAT were 
prescribed because of concomitant coronary revascularization. Median follow up was 12 months. Outcomes are reported in the table: no significant 
differences were found among various groups; no prosthetic valve thrombosis occurred. 
Control group Patients with indication for AC (n=60) P-valueAC ± antiplatelet AC + 1 antiplatelet AC Only DAT only AC + DAT
N 300 58 43 14 2 1 -
Mortality 41 (15.3) 6 (10.3) 6 (14.3) 0 0 1 (100) 0.112
Bleeding
Intracranial
Life-trhreat.
Major
3 (1)
70 (24.4)
95 (33.1)
1 (1.7)
13 (22.4)
12 (20.7)
1 (2.3)
10 (23.3)
11 (25.6)
0
3 (27.3)
1 (9.1)
0
0
0
0
1 (100)
0
0.938
0.479
0.339
Stroke 6 (2.2) 0 0 0 0 0 0.881
TIA 7 (2.6) 0 1 (2.4) 0 0 0 0.990
Conclusion: When AC is prescribed after TAVI, many variables must be taken into account, such as compliance and concomitant presence of 
coronary artery disease. The most frequent scenario is represented by patients in AF: we believe that these patients can be safely discharged 
in therapy with AC plus a single antiplatelet agent. If bleeding is a concern, especially if no coronary disease is present, AC alone could be 
recommended. If the patient is expected not to comply with AC, DAT may be a reasonable alternative.
